Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study

Stefania Gori, Alessandro Inno, Valentina Rossi, Monica Turazza, Elena Fiorio, Alessandra Fabi, Giancarlo Bisagni, Jennifer Foglietta, Daniele Santini, Ida Pavese, Arianna Pellegrino, A. Zambelli, Patrizia Vici, Vita Leonardi, Sandro Barni, S. Saracchini, Giuseppe Bogina, Fabiana Marchetti, Simona Duranti, Gianluigi LunardiFilippo Montemurro

Research output: Contribution to journalArticle

Abstract

Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p

Original languageEnglish
Article numbere0156221
JournalPLoS One
Volume11
Issue number5
DOIs
Publication statusPublished - May 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gori, S., Inno, A., Rossi, V., Turazza, M., Fiorio, E., Fabi, A., Bisagni, G., Foglietta, J., Santini, D., Pavese, I., Pellegrino, A., Zambelli, A., Vici, P., Leonardi, V., Barni, S., Saracchini, S., Bogina, G., Marchetti, F., Duranti, S., ... Montemurro, F. (2016). Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study. PLoS One, 11(5), [e0156221]. https://doi.org/10.1371/journal.pone.0156221